The treatment of advanced pancreatic cancer: Current evidence and future challenges

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Moore, M J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; MARIMASTAT; MATRIX METALLOPROTEINASE; OXALIPLATIN; PEMETREXED; PLACEBO; SMAD4 PROTEIN; SORAFENIB; SUNITINIB; TANOMASTAT; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; INFECTION; KIDNEY CARCINOMA; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; ADENOCARCINOMA; ARTICLE; DRUG DELIVERY SYSTEM; FORECASTING; GENETICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; PANCREATIC NEOPLASMS;

EID: 53449089231     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn461     Document Type: Conference Paper

References (40)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics. 2006. Toronto: Canadian Cancer Society/National Cancer Institute of Canada.
2. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206: 358-365.
3. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 89: 1-7.
4. Bardeesy N, DePinho RA. Pancreatc cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
5. Almoquera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
6. Lemoine NR, Jain S, Hughes CM et al. K-ras oncogene activation in pre-invasive pancreatic cancer. Gastroenterology 1992; 102: 230-236.
7. Kayed H, Kleeff J, Osman T et al. Hedgehog signaling in the normal and diseased pancreas. Pancreas 2006; 32: 119-129.
8. Zhu J, Abbruzzese JL, Izzo J et al. AURKA amplification, chromosome instability and chromosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 2005; 159: 10-17.
9. Hata T, Furukawa T, Sunamura M et al. RNA interference targeting aurora knase suppresses tumour growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65: 2899-2905.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
11. BieTie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
12. Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 2003; 4: 237-256.
13. Abe K, Suda K, Arakawa A, Yamasaki S. Different patterns of p161NK4A and p53 protein expressions in intraductal papillary mucious neoplasm and pancreatic neoplasia. Pancreas 2007; 34: 85-91.
14. Bardeesy N, Aquirre AJ, Chu GC. Both pl6(lnk4a)- p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-5952.
15. Burris HA III, Moore M, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
16. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed dose rate infusion) versus gemcitabine + oxaliplatin (GEMOX) in patents with advanced pancreatic cancer (E6201). Proc Am Soc Clin Oncol 2006: (abstract LBA4004).
17. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pernetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645.
18. Rocha Lima CM, Green M, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer patients despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783.
19. Macdonald JS, McCoy S, Whitehead RP et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG 9924) study. Invest New Drugs 2005; 23: 485-487.
20. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifamib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
21. Haq M, Shafii A, Zervos EE, Rosemurgy AS. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res 2000; 60: 3207-3211.
22. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patents with unresectable pancreatic cancer; a randomized trial. J Clin Oncol 2001; 19: 3447-3455.
23. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patents with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167.
24. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas; a phase 3 trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-3302.
25. Ueda S, Ogata S, Tsuda H et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29: E1-E8.
26. Bruns CJ, Solorzano CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine knase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-2935.
27. Dragovish T, Patnaik A, Rowinsky E et al. A phase IB trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancy. Proc Am Soc Clin Oncol 2003; (abstract 895).
28. Porterfield BW, Dragovich T, Patnaik A et al. Erlotinib and gemcitabine in patients with unresectable pancreatic carcinoma: Results from a IB trial. Proc Am Soc Clin Oncol 2004; (abstract 4110).
29. Moore MJ, Goldstein D, Hamm J et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
30. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockage with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-1948.
31. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J Clin Oncol 2004; 22: 2610-2666.
32. Philip P, Benedetti, J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc Am Soc Clin Oncol 2007; (abstract 4509).
33. Safran H, Iannitti D, Ramanathan R et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22: 706-712.
34. Folkman J. Tumour angiogenesis: Therapeutic implications. New Engl J Med 1971; 285: 1182-1186.
35. Kindler HL, Friburg G, Singh GA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-8040.
36. Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC]: A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Proc Am Soc Clin Onool 2007; (abstract 4508).
37. Siu LL, Awada A, Takimoto CH et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumours with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006; 12: 144-151.
38. Wallace JA et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium. 2007 Gastrointestinal Cancers Symposium; abstract 137.
39. Tuhackova Z. Molecular therapeutics - lessons from the role of Src in cellular signaling. Folia Biol (Praha) 2005; 51: 114-120.
40. Nimwegan MJ, van de Water B. Focal adhesion kinase: A potential target in cancer therapy. Biochem Pharmacol 2007; 73: 597-609.